These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. New perspectives in cardiology: pharmacodynamic classification of antiarrhythmic drugs. Adams HR J Am Vet Med Assoc; 1986 Sep; 189(5):525-32. PubMed ID: 2875984 [TBL] [Abstract][Full Text] [Related]
8. [Clinical pharmacology of anti-arrhythmia agents. III. Drugs blocking beta adrenergic receptors]. Witkowska M Kardiol Pol; 1982; 25(2):147-61. PubMed ID: 6125621 [No Abstract] [Full Text] [Related]
9. Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Packer M Circulation; 1990 Aug; 82(2 Suppl):I77-88. PubMed ID: 1973643 [TBL] [Abstract][Full Text] [Related]
11. Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists. Packer M J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S38-43. PubMed ID: 2478808 [TBL] [Abstract][Full Text] [Related]
12. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988 [TBL] [Abstract][Full Text] [Related]
13. [Current classification of anti-arrhythmia agents]. Weirich J; Wenzel W Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787 [TBL] [Abstract][Full Text] [Related]
14. Age-related alterations in the cardiovascular response to adrenergic mediated stress. Lakatta EG Fed Proc; 1980 Dec; 39(14):3173-7. PubMed ID: 6108242 [TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. [Adrenergic betareceptors and cardiac insufficiency]. Weber S; Cabanes L; Guérin F Arch Mal Coeur Vaiss; 1990 Nov; 83(13):1957-61. PubMed ID: 1980187 [TBL] [Abstract][Full Text] [Related]
17. Sympatho-adrenergic activation of the ischemic myocardium and its arrhythmogenic impact. Schömig A; Richardt G; Kurz T Herz; 1995 Jun; 20(3):169-86. PubMed ID: 7635399 [TBL] [Abstract][Full Text] [Related]
18. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects]. Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348 [TBL] [Abstract][Full Text] [Related]
19. [Unwanted drug interaction between anti-arrhythmic drugs and drugs used for heart failure]. Jaźwińska-Tarnawska E; Orzechowska-Juzwenko K Pol Merkur Lekarski; 2000 Sep; 9(51):614-7. PubMed ID: 11126988 [TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic drug therapy: new drugs and changing concepts. Reiser HJ; Sullivan ME Fed Proc; 1986 Jul; 45(8):2206-12. PubMed ID: 2873062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]